Roconkibart vs UA026

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Psoriasis

Shared mechanism: IL-17A · full Psoriasis pipeline

Roconkibart

Developed by Shanghai Junshi Bioscience and partners

Phase 3 in Psoriasismonoclonal antibody
Reliable signal

NCT05975268 · Phase 3 · completed

The trial randomized participants to JS005 150mg, 300mg, or placebo with full blinding of participants, care providers, investigators, and outcomes assessors, in a reasonably large phase 3 population of 747 patients. The primary endpoints -- PASI 90 and sPGA 0/1, both standard hard clinical measures of psoriasis severity -- were reported as met with statistically significant improvement over placebo, satisfying the design and result standards for strong evidence.

Result from the sponsor's press release or a wire copy of it; no peer-reviewed publication or posted registry results were found.

Reported efficacy

Change in PASI 90 (From week 0 to week 12); Change in sPGA (From week 0 to week 12): Both co-primary endpoints and key secondary endpoints showed statistically significant and clinically meaningful improvements (met)

Result source: NCT05975268

UA026

Developed by Usynova Pharmaceuticals Ltd.

Phase 1 in Psoriasissmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Psoriasis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointRoconkibartUA026
PASI 75—Not posted · NCT05975268—Not reported
PASI 90—Not posted · NCT05975268—Not reported
PASI 100—Not posted · NCT05975268—Not reported
sPGA 0/1—Not posted · NCT05975268—Not reported
DLQI, change—Not posted · NCT05975268—Not reported

PASI 75

Roconkibart
—Not posted · NCT05975268
UA026
—Not reported

PASI 90

Roconkibart
—Not posted · NCT05975268
UA026
—Not reported

PASI 100

Roconkibart
—Not posted · NCT05975268
UA026
—Not reported

sPGA 0/1

Roconkibart
—Not posted · NCT05975268
UA026
—Not reported

DLQI, change

Roconkibart
—Not posted · NCT05975268
UA026
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

UA026: no structured comparison results are available for Psoriasis.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Roconkibart
Both co-primary endpoints and key secondary endpoints showed statistically significant and clinically meaningful improvements NCT05975268 · Phase 3 · design grade: strong · publication or press release

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Roconkibart's landscape · UA026's landscape